TuisAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Vorige sluiting
$2,59
Dagwisseling
$2,53 - $2,67
Jaarwisseling
$2,33 - $20,35
Markkapitalisasie
7,02 m USD
Gemiddelde volume
77,89 k
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 25,00 k | -50,00% |
Bedryfskoste | 2,66 m | -28,77% |
Netto inkomste | -2,79 m | -52,18% |
Netto winsgrens | -11,18 k | -204,36% |
Wins per aandeel | -3,68 | -22,67% |
EBITDA | -2,59 m | 28,68% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 835,00 k | -91,70% |
Totale bates | 4,13 m | -73,73% |
Totale aanspreeklikheid | 10,68 m | 11,05% |
Totale ekwiteit | -6,55 m | — |
Uitstaande aandele | 2,71 m | — |
Prys om te bespreek | -0,30 | — |
Opbrengs op bates | -127,49% | — |
Opbrengs op kapitaal | 260,64% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -2,79 m | -52,18% |
Kontant van bedrywe | -1,53 m | 49,10% |
Kontant van beleggings | 754,00 k | -8,72% |
Kontant van finansiering | 355,00 k | -85,46% |
Netto kontantverandering | -422,00 k | -262,93% |
Beskikbare kontantvloei | -1,37 m | 65,91% |
Meer oor
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Gestig
1966
Webwerf
Werknemers
22
